Drug-Resistant Fungus Spreads in European Hospitals
- A rapidly spreading drug-resistant fungus,Candidozyma auris (C.
- auris) is an emerging multidrug-resistant yeast that poses a notable threat to healthcare settings.first identified in 2009 in Japan, it has sence spread globally, causing outbreaks in hospitals...
- The fungus is particularly perilous as it frequently enough resists common antifungal drugs, including azoles and echinocandins.
“`html
Drug-Resistant Fungus *Candidozyma auris* Spreads Across Europe,Raising Alarm
Table of Contents
A rapidly spreading drug-resistant fungus,Candidozyma auris (C. auris), is prompting urgent warnings from European health officials. The European Centre for Disease Prevention and Control (ECDC) reports increasing case numbers and outbreaks, signaling a serious threat to vulnerable patients and healthcare systems.
What is *Candidozyma auris*?
Candidozyma auris (C. auris) is an emerging multidrug-resistant yeast that poses a notable threat to healthcare settings.first identified in 2009 in Japan, it has sence spread globally, causing outbreaks in hospitals and long-term care facilities. Unlike many other fungi, C. auris can survive on surfaces for extended periods, contributing to its persistence and spread.
The fungus is particularly perilous as it frequently enough resists common antifungal drugs, including azoles and echinocandins. This leaves limited treatment options for infected patients. Furthermore, C. auris can cause bloodstream infections, wound infections, and ear infections, and has a high mortality rate, especially in individuals with compromised immune systems.
The European Situation: Rising Cases and Transmission
The ECDC’s recent report highlights a concerning trend: both the number of C. auris cases and the number of outbreaks are increasing across Europe. Several countries have reported ongoing local transmission, indicating that the fungus is establishing itself within healthcare facilities. The ECDC doesn’t specify *which* countries are most affected in its initial report, but stresses the need for coordinated surveillance.
The report emphasizes that most patients infected with C. auris already have serious underlying health conditions, making it difficult to isolate the fungus as the sole cause of illness. However, the increasing prevalence and drug resistance of C. auris significantly worsen the prognosis for these vulnerable individuals.
| Year | Reported C. auris Cases (EU/EEA) |
|---|---|
| 2021 | 168 |
| 2022 | 304 |
| 2023 | 588 |